ACR 2020 Tweet by Robert B Chao, MD
Tweet
Related Content
DERM on RheumNow PODCAST (September 2026)
Sep 30, 2026
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors.Features Dr. Jack Cush, Editor at RheumNow.com.Show Notes:FDA Grants Priority Review…
POETYK PsA-1 - Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis
Jack Cush, MD
Oct 6, 2026
van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and structural damage inhibition in patients with psoriatic arthritis (PsA).
Podcast
DERM on RheumNow PODCAST (October 2026)
RheumNow
Oct 31, 2026
Every day, every month, rheumatology publishes news and reports on JAK inhibitors, IL-17s, IL-23s, lupus, myositis, and scleroderma – all which could change how you practice dermatology. I'm Jack Cush from RheumNow, and This is Derm on RheumNow.
This month’s podcast will Scratch the surface and…
